Inventor · disambiguated record
Ryan Dittamore
Also filed as: DITTAMORE RYAN
2 granted patents·29 pending applications·4 citations·filing 2012–2024
44Inventor score
Top patents by PatentIndex Score
31 records- 0177US10527624B2Circulating tumor cell diagnostics for prostate cancer biomarkersEPIC SCIENCES INC·Filed 2015·Granted Jan 7, 2020·4 cites·14 claims
- 0277US2025180564A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0372US2024319193A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 0471US2025130236A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0568US2024103003A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 0668US2025155440A1Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic diseaseEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0764US2022390451A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2022·Application pending·0 cites
- 0863US2021405055A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 0963US2024036047A1ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)EPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 1062US2022091124A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1162US2022162706A1Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)EPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1259US2023033449A1Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)EPIC SCIENCES INC·Filed 2022·Application pending·0 cites
- 1358US2021382057A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1458US2021373026A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1556US2022091123A1Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapiesEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1654US2020333345A1Circulating tumor cell diagnostics for prostate cancer biomarkersEPIC SCIENCES INC·Filed 2019·Application pending·0 cites
- 1753US10082508B2Automated analysis of circulating tumor cellsVENTANA MED SYST INC·Filed 2016·Granted Sep 25, 2018·0 cites·43 claims
- 1853US2018321247A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 1951US2018052167A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2017·Application pending·0 cites
- 2049US2019025312A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2017·Application pending·0 cites
- 2148US2022260574A1Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic diseaseEPIC SCIENCES INC·Filed 2018·Application pending·0 cites
- 2248US2018155794A1Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)EPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 2347US2013171642A1Automated analysis of circulating tumor cellsPESTANO GARY·Filed 2012·Application pending·0 cites
- 2446US2015212089A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2544US2016011198A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2644US2016341732A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2743US2019285636A1ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)EPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 2841US2017285035A1Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapiesEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2940US2016040245A1Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 3038US2012220672A1Presence of ERG Gene Rearrangements and Protein Over-expression in Low Grade PIN (LG-PIN) in Prostate BiopsiesPESTANO GARY·Filed 2012·Application pending·0 cites
- 3126US2017242016A1Circulating tumor cell diagnostics for therapy targeting pd-l1EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ryan Dittamore files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →